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Abstract
Microglia, the immune cells of the brain, are important for neurodevelopment and have
been hypothesized to play a role in the pathogenesis of schizophrenia (SCZ). Although
previous postmortem studies pointed toward presence of microglial activation, this
view has been challenged by more recent hypothesis-driven and hypothesis-free ana-
lyses. The aim of the present study is to further understand the observed microglial
changes in SCZ. We first performed a detailed meta-analysis on studies that analyzed
microglial cell density, microglial morphology, and expression of microglial-specific
markers. We then further explored findings from the temporal cortex by performing
immunostainings and qPCRs on an additional dataset. A random effect meta-analysis
showed that the density of microglial cells was unaltered in SCZ (ES: 0.144 95% CI:
0.102 to 0.390, p = .250), and clear changes in microglial morphology were also absent.
The expression of several microglial specific genes, such as CX3CR1, CSF1R, IRF8,
OLR1, and TMEM119 was decreased in SCZ (ES: −0.417 95% CI: −0.417 to −0.546,
p < .0001), consistent with genome-wide transcriptome meta-analysis results. These
results indicate a change in microglial phenotype rather than density, which was vali-
dated with the use of TMEM119/Iba1 immunostainings on temporal cortex of a sepa-
rate cohort. Changes in microglial gene expression were overlapping between SCZ and
other psychiatric disorders, but largely opposite from changes reported in Alzheimer's
disease. This distinct microglial phenotype provides a crucial molecular hallmark for
future research into the role of microglia in SCZ and other psychiatric disorders.
K E YWORD S
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1 | INTRODUCTION
Genetic and epidemiological studies have suggested a causal role for
the immune system in schizophrenia (SCZ) pathogenesis (Benros
et al., 2014; Pouget et al., 2019; Ripke et al., 2014; Sekar et al., 2016;
van Mierlo, Schot, Boks, & de Witte, 2019). This is supported by
changes in immune-related markers reported in blood, cerebrospinal
fluid, and brain tissue of SCZ patients (Gandal et al., 2018;
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Upthegrove, Manzanares-Teson, & Barnes, 2014; Wang &
Miller, 2018). It has, therefore been hypothesized that microglia, the
immune cells of the brain, play an important role in SCZ (Howes &
McCutcheon, 2017). Microglia are part of the innate immune system
and regulate inflammatory responses in the central nervous system
(CNS) (Tambuyzer, Ponsaerts, & Nouwen, 2009). Microglia also con-
trol synaptic pruning, a process thought to be dysregulated in SCZ
(Berdenis van Berlekom et al., 2019). Synaptic pruning is required for
normal brain development and is mediated through the complement
cascade (Stephan, Barres, & Stevens, 2012). Copy number variants in
complement factor 4A (C4A) are associated with SCZ (Sekar
et al., 2016), and increased synaptic pruning was observed in patient-
derived microglial cell cultures (Sellgren et al., 2019).
Many brain disorders coincide with microglial activation, a state
characterized by an increased cell density, and a morphological
shift from ramified toward amoeboid, and upregulated expression of
several inflammatory molecules (Kettenmann, Hanisch, Noda, &
Verkhratsky, 2011). A previous review and independent meta-analysis
(Trépanier, Hopperton, Mizrahi, Mechawar, & Bazinet, 2016; Van
Kesteren et al., 2017) suggested an activated microglia phenotype in
postmortem brain tissue of patients with SCZ. However, these reviews
also noted substantial heterogeneity between studies, and a generally
limited number of subjects, ranging from N = 5–35. This heterogeneity
is probably caused by a large variety of pre- and postmortem con-
founders, methodological differences, and analysis of divergent brain
regions (Powchik et al., 1998). In addition, samples that partially over-
lapped between the studies were included in the meta-analysis. In con-
trast, three recent genome-wide transcriptomic studies on SCZ
postmortem brain tissue, with sample sizes ranging from N = 159–559
patients (Bergon et al., 2015; Gandal et al., 2018; Gandal, Zhang,
et al., 2018), did not find increased expression of most of these micro-
glial markers. Instead, the expression of several well-known microglial
genes, such as CX3CR1, TMEM119, TREM2, CSF1R, ITGAM, CD86, and
OLR1, were downregulated in one or more of these studies.
The goal of the present study was to better understand these
reported microglial changes in schizophrenia. Our aim was to provide an
up-to-date overview of hypothesis-driven studies that analyzed micro-
glial density, morphology, and expression of microglial-specific genes.
We performed a structural review followed by a qualitative and quantita-
tive assessment of the selected studies. We included an additional
dataset using postmortem samples from the Netherlands (NBB) and
Edinburgh Brain Banks (EBB) to explore previous significant microglial
findings in the temporal cortex (Van Kesteren et al., 2017). In addition,
we further elucidate changes in mRNA expression identified by the
aforementioned hypothesis-free transcriptomic studies on bulk brain tis-
sue (Gandal, Zhang, et al., 2018). By applying a recently published core
microglial signature (Patir, Shih, McColl, & Freeman, 2019) on this
dataset we identified up- and downregulated genes that are likely to
reflect changes in microglia. We analyzed how these microglia-related
changes overlap with gene expression changes in other disorders, such
as autism spectrum disorder (ASD), bipolar disorder (BPD), and
Alzheimer's disease (AD). Altogether, this study provides an overview of
microglial changes in postmortem brain tissue of patients with SCZ.
2 | MATERIAL AND METHODS
2.1 | Meta-analysis
2.1.1 | Search strategy
The quantitative review was performed according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
(Liberati et al., 2009). We performed two separate systematic searches
for articles analyzing microglial density and morphology changes or
changes in microglial-specific gene expression. We used PubMed and
EMBASE, and checked references of included studies and previous
reviews (Suzuki et al., 2019;Trépanier et al., 2016; Van Kesteren
et al., 2017). We used the following search terms: (a) (postmortem OR
postmortem OR autopsy) AND (schizophreni* OR psychotic OR psy-
chosis) AND (microgli* OR macrophage*); (b) (postmortem OR postmor-
tem OR autopsy) AND (AIF1 OR IBA1 OR Iba-1 OR CD68 OR NOX2
OR CYBB OR HLADR* OR HLA-DR* OR P2RY12 OR P2Y12 OR
TMEM119 OR CX3CR1 OR ITGB2 OR ITGAX OR CD11c OR GPR34
OR CSF1R OR IRF8 OR TGFB1 OR TREM2 OR DAP12 OR TYROBP
OR OLR1) AND (schizophreni* OR psychotic OR psychosis). The
microglia markers (n = 17) were selected because they were used as
microglia markers in studies that came out of our first search and recent
reviews (Trépanier et al., 2016; Van Kesteren et al., 2017), or that have
been more recently described as microglia-specific markers (Bennett
et al., 2016; Butovsky et al., 2014). Furthermore, these markers are spe-
cifically expressed in microglia compared to other cells in the CNS and
are all part of a defined microglial signature recently described by (Patir
et al., 2019). We excluded transcriptomic studies (micro-array and RNA
sequencing) from the meta-analysis, since we assumed a high chance of
selection/reporting bias, as only significant results were reported in most
of these studies. However, to validate our meta-analysis findings, we
extracted results from the largest transcriptomic study in SCZ to date,
which includes data on all detected genes (Gandal, Zhang, et al., 2018).
The search cut-off date was February 28, 2020. Screening and selection
of studies were performed independently by three authors (GS, WZ, and
LW). Disagreements were resolved through discussion.
2.1.2 | Inclusion criteria
Pre-specified inclusion criteria were: (a) human postmortem studies;
comparing (b) patients with a diagnosis of SCZ with (c) healthy con-
trols; (d) measuring microglial density or gene expression of microglial
markers; (e) original research, published in a peer-reviewed journal;
and (f) written in English.
2.1.3 | Qualitative assessment
Several criteria were assessed to evaluate the quality of the included
studies. Study design was rated for the following aspects: blinding
researchers to diagnostic or clinical information, neuropathological
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assessment, the degree of matching of control and patient population,
and whether correction of general (age/PMI) and other confounding
factors, such as medication use, pH, cause of death, illness duration,
age of onset, was applied. Methodology was assessed for complete
description of technical methods and subsequent analyses. For
reporting, studies were evaluated for whether important details
regarding psychopathologic examination, population demographics,
and main outcome variables could be retrieved (Tables S5 and S11).
2.1.4 | Data extraction
When data records in the original article were not given or insufficient
to generate effect sizes, corresponding authors were asked to provide
raw data. In the case of follow-up data, included outcomes of the larg-
est sample size were included. If data were not reported numerically
in the manuscript, data was extracted using https://automeris.io/
WebPlotDigitizer/. The following variables were extracted for poten-
tial moderator analyses: sample size, methods, brain bank, brain region
and area (cortical or subcortical), age, sex, postmortem interval (PMI),
and pH (Tables S6, S7, S8, S12 and S13).
2.1.5 | Statistical approach meta-analysis
Meta-analyses were carried out using the Comprehensive Meta-
Analysis (CMA) software developed by Biostat (Borenstein, Hedges,
Higgins, & Rothstein, 2009). Change in microglial number or microglial
gene expression per brain (sub)region was used to quantify effect size
(ES) between SCZ and controls. We used sample size, mean, and stan-
dard deviation (SD) to generate ES. Hedges's g and the upper/lower
limit of the 95% CI were used to express ES. Given the heterogeneity
among studies, we used a random effects model for all comparisons
(Higgins, Thompson, & Spiegelhalter, 2009). The Cochran's Q-statistic
test, displaying a chi-square distribution with k − 1 degrees of free-
dom, was performed to evaluate the existence of heterogeneity. High
Q-values indicate that the variability among studies is higher than
would be expected due to randomness, and further examination of
subgroups is warranted. I-squared (I2) was calculated to estimate the
amount of heterogeneity. I2 reflects which proportion of the observed
variance reflects differences in true effect size rather than sampling
error (range 0–100%) (Higgins, 2003). Potential outlier studies were
defined as those with standardized residual z-scores of effect sizes
exceeding ±1.96 (p ≤ .05 two tailed). The potential for publication bias
was assessed by visual examination of Funnel plots and by the Egger's
test (which was considered significant if the one-sided p-value was
≤.10) (Egger, Smith, Schneider, & Minder, 1997). Random-effects
meta-regression analyses were performed to analyze the role of
potential confounding factors (age, sex, PMI, pH). An exploratory sub-
group analysis was performed on biological variables (brain regions,
technical variation (methods, outcome measures) to assess sources of
heterogeneity. We grouped outcomes for analyzing different brain
regions in four subgroups: frontal cortex (including the dorsal, ventral,
and dorsolateral prefrontal cortex, orbitofrontal cortex, midfrontal
cortex, entorhinal cortex), temporal cortex, occipital cortex and limbic
system (including the mid(anterior) cingulate cortex, hippocampus,
amygdala, thalamus, dorsal raphe nucleus, basal ganglia). A common
among-study variance was assumed across different subgroups, and
within-group estimates of tau-squared were pooled. Between-group
differences were tested using the Q-test based analysis of variance to
determine whether the variance within subgroups was significantly
smaller than the variance of all the combined data
(Qbetween = Qtotal − (QSubgroupA + QSubgroupB). Cell density and
gene expression studies were analyzed separately. For the microglial
cell density studies, each study included only one marker (or a double
staining) as outcome measurement, but various studies included multi-
ple brain regions. Microglial cell density and gene expression measure-
ments in different brain regions within the same cohort/study are not
independent of each other. To prevent overrepresentation of the
results from studies analyzing multiple brain regions in our analysis
across all brain regions, we therefore used a conservative approach
and nested data by computing combined scores from all measure-
ments across different brain regions within one study. Forest plots of
unnested data are depicted in the Figures of Supporting Information.
2.2 | SCZ cohort
2.2.1 | Human brain tissue
Paraffin-embedded and frozen postmortem samples of the superior tem-
poral gyrus were provided by the Netherlands (Rademaker, de Lange, &
Palmen, 2018) and Edinburgh Brain Banks (Millar et al., 2007) (NBB and
EBB). The permission to collect human brain material was obtained from
the Ethical Committee of the VU University Medical Center, Amsterdam,
The Netherlands, and the East of Scotland Research Ethics Service
REC1. Permission for brain autopsy and the use of brain tissue and
accompanying clinical information for research purposes was obtained
per donor ante-mortem. Control donors were defined as donors without
a clinical diagnosis of a major depressive disorder, bipolar disorder, or
psychotic disorder according to the DSM-IV, DSM-III-R, or DSM-III. If
the DSM classification was not available, the DSM characterization was
based on retrospective medical chart review by two independent psychi-
atrists. Cases clinically diagnosed with Alzheimer's or Parkinson's disease,
Amyotrophic Lateral Sclerosis, Multi System Atrophy, or brain diseases
caused by an infection (meningitis and encephalitis) were excluded.
There was no significant difference between controls and patients in
age, sex, postmortem interval (PMI), or pH (Table S1). Detailed clinico-
pathological information per donor is provided in Table S2.
2.2.2 | Iba1 immunohistochemistry
Microglial density and morphology were characterized by ionized
calcium-binding adapter molecule 1 (Iba1) immunohistochemistry as
described before (Sneeboer et al., 2019). Paraffin-embedded tissue of
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the superior temporal gyrus was sectioned at 7 μm for SCZ patients
(N = 12) and controls (N = 16). The sections were deparaffinized using
a standard xylene and alcohol series, followed by blocking of endoge-
nous peroxidase with PBS, 1% H2O2 (Merck, Germany). For antigen
retrieval, sections were heated in 0.01 mM citrate buffer (Merck,
Darmstadt, Germany), 0.05% Tween-20 (Merck, Darmstadt, Ger-
many), pH = 6.0 for 15 min. Subsequently, nonspecific binding was
blocked in PBS with 1% normal horse serum (NHS, Thermo Fisher Sci-
entific, MA), 0.1% bovine serum albumin (BSA, Merck, Darmstadt,
Germany), and 0.2% Triton X (Merck, Darmstadt, Germany). Sections
were subsequently incubated with a rabbit polyclonal anti-Iba1 anti-
body (Wako Pure Chemical Industries, Ltd., 1:1000) at 4C. Next day,
secondary goat-anti-rabbit biotin (Jackson ImmunoResearch Labora-
tories, Inc., 1:400) was added, followed by avidin-biotin-peroxidase
(AB) complex (Vector Laboratories). To visualize the microglia, the sec-
tions were incubated with a 3,30 diaminobenzidine (DAB) substrate
(DAKO). Finally, tissue sections were dehydrated using an alcohol and
xylene series and embedded in Entellan (Merck, Darmstadt, Germany).
Iba1-DAB stainings were visualized with a ZEISS Imager M2 light
microscope. Per tissue section, six pictures of 615 x 450 μm were ran-
domly taken throughout the cortex blinded for diagnosis. A qualitative
assessment was done of the microglial morphology in each picture, as
previously described by (Torres-Platas, Cruceanu, Chen, Turecki, &
Mechawar, 2014), classifying them into a ramified, primed, reactive or
amoeboid category. Open-source software ImageJ was used to quan-
tify microglial cell numbers and Iba1 positive area covered. A particle
analysis macro-script was used to count microglial cell numbers of the
DAB staining. The macro consisted of the following steps: transforma-
tion to 8-bit; scaling of pixels to μm (according to microscope guide-
lines); automated default threshold application (minimum radius mask
of 1 and maximum radius mask of 3); conversion to mask; particle fil-
tration with size > 80; option “outline” and “exclude cells on the
edge”. Thereafter, the average number of microglial cells of six pic-
tures was calculated and divided by the area of the pictures. This
method was previously validated (Sneeboer et al., 2019). The macro
for the Iba1 positive area covered consisted of the following steps:
transformation to 8-bit; scaling of pixels to μm (according to micro-
scope guidelines); automated default threshold application; conver-
sion to mask; particle filtration with size > 0.01, option “outline”,
“exclude cells at edge” and “summarize”. The pictures were manually
viewed, pictures with poor performance were excluded, and the Iba1
positive-area covered was averaged for the 3–6 non-excluded
pictures.
2.2.3 | Iba1/TMEM119 immunofluorescence
Immunofluorescence double staining with Iba1 and Transmembrane
Protein 119 (TMEM119) antibodies was performed by sectioning
paraffin-embedded tissue of the superior temporal gyrus at 7 μm for
SCZ patients (N = 18) and controls (N = 19). After deparaffinization,
blocking of endogenous peroxidase, antigen retrieval, and blocking of
nonspecific binding with normal horse serum, sections were incubated
with a polyclonal goat anti-Iba1 antibody Ab5076 (Abcam) and a poly-
clonal rabbit anti-TMEM119 antibody HPA051870 (Atlas Antibodies).
This was followed by staining with donkey anti-rabbit Alexa Fluor
488 and donkey anti-goat Cy3 antibodies (Jackson Immunoresearch
Laboratories), as well as Hoechst (Thermo Scientific). Images
(615 × 450 μm) of six randomly selected areas throughout the grey
matter of the cortex were collected with a Zeiss Axio Scope A1 fluo-
rescence microscope. Most cells were positive for both Iba1 and
TMEM119. While we only rarely observed cells that were TMEM119+
and Iba1−, we found a variable degree of Iba1+/TMEM119− across
donors. To analyze case–control differences, we calculated the per-
centage of TMEM119+/Iba1+ by dividing the number of TMEM119+/
Iba1+ cells by the total number of Iba1+ cells, both manually counted.
2.2.4 | Gene expression analysis
Five 50 μm sections of grey matter of the superior temporal gyrus
were dissected manually from cryosections for SCZ patients (N = 9)
and controls (N = 14). RNA was isolated using Trizol reagent (Thermo
Fisher Scientific, MA), followed by addition of 100 μl chloroform and
centrifugation at 12,000 rcf at 7C for 15 min. Subsequently, RNA
was precipitated from 100–200 μl of the aqueous top phase by mixing
with an equal volume of isopropanol, using 1 μl glycogen as a carrier,
and stored overnight at −20C. The next day, samples were cen-
trifuged at maximum speed at 4C for 60 min. The pellet was washed
twice with 75% ETOH, air-dried, and dissolved in 8 μl Milli-Q water.
Concentrations of extracted RNAs were measured using a nanodrop
(ND-1000; NanoDrop Technologies, Rockland, DE). RNA was
reversed transcribed using a Quantitect Reverse Transcription kit
(QIAGEN, Hilden, Germany) according to the manufacturer's protocol.
RNA supplemented with Milli-Q water to a volume of 6 μl was mixed
with 1 μl gDNA Wipe-Out buffer and incubated at 42C for 2 min.
After addition of the master mix containing 2 μl Reverse-Transcriptase
buffer, 0.5 μl Reverse-Transcriptase enzyme, and 0.5 μl RT random
hexamers primer mix, samples were incubated at 42C for 30 min,
followed by 95C for 3 min. Samples were subsequently stored at
−20C until further use. Quantitative real-time polymerase chain reac-
tion (qPCR) was performed on a QuantStudio™ 6 Flex Real-Time PCR
System (Life Technologies Corporation, NY). Per reaction, 3.5 ng input
of cDNA was mixed with Milli-Q water, 5 μl SYBRgreen PCR Master
Mix (Roche; Life Technologies Corporation, Grand Island, NY), and
1 μl primer mix (2 pmol/mL; see Table S3) until a final volume of 11 μl.
All primers were intron-spanning and designed with the online tool of
NCBI. The following cycle conditions were used: 50C for 2 min, 95C
for 10 min, 40 cycles at 95C of 15 s, and at 60C for 60 s. Gene
expression was normalized to reference genes (Glyceraldehyde
3-phosphate dehydrogenase (GAPDH), β-actin (ACTB), and Succinate
Dehydrogenase Complex Flavoprotein Subunit A (SDHA)) according
to the ΔΔCT method. These genes were selected from a larger set of
housekeeping genes based on the Vandesompele method
(Vandesompele et al., 2002). Gene expression values were compared
with other gene expression studies by dividing the mean ΔCT scores
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of SCZ patients by the mean of the controls and applying a log2 trans-
formation. The relative gene expression was expressed as a log2 fold
change (log2FC) value.
2.2.5 | Statistics
Statistical analysis was performed with SPSS IBM 25. Assumption of
normality was tested by visual checks using histograms and by the
Shapiro Wilk test. Mann–Whitney U tests were applied to test the dif-
ferences between patients and controls. Spearman rank correlation
tests were used to determine the relation between age, PMI, pH, sex,
and microglial density (Iba1+-cells/mm2 and total Iba1+ -area covered)
and the microglial gene expression analysis. Subsequently, an
ANCOVA analysis was performed to study the interaction effects of
these covariates on microglial density and microglial gene expression.
In the case of non-normally distributed data, log transformation was
used. Results were adjusted for multiple testing by dividing the proba-
bility level of p < .05 by the number of performed tests.
2.3 | Cross-disorder comparison of microglial gene
expression changes
We used a recently identified core signature of N = 249 genes that
are specifically expressed by microglia compared to other CNS cell-
types (Patir et al., 2019). We extracted differential gene expression
data of these genes (log2 fold changes) from the largest bulk brain tis-
sue transcriptome studies on SCZ (Gandal, Zhang, et al., 2018), BD
(Gandal, Zhang, et al., 2018), ASD (Gandal, Zhang, et al., 2018), and
AD (Friedman et al., 2018). Correlations between log2 fold changes in
different conditions and the significance of these correlations were
calculated with the R function rcorr in R package Hmisc
(Harrell, 2020). Overlaps between up- and downregulated genes in
SCZ versus the other disorders were determined and tested for signif-
icance using the R function fisher.test (Harrell, 2020).
3 | RESULTS
3.1 | Literature search microglial density and
morphology studies
After title and abstract screening for inclusion and exclusion criteria,
38 studies were selected for full-text assessment. Twenty-two studies
were excluded (Table S4), including two studies (Busse et al., 2012;
Steiner et al., 2006) containing samples that overlapped with other
studies (Gos et al., 2014; Steiner et al., 2008). The study with the larg-
est sample size was included. The database searches in PubMed and
EMBASE, and additional records identified via cross-referencing,
yielded a total of 16 records (Figure S1) that were all included in the
qualitative assessment (Table S5). Authors of six studies (Comte,
Kotagiri, & Szele, 2012; Connor, Guo, & Akbarian, 2009; Fillman
et al., 2013; Foster et al., 2006; Schnieder et al., 2014; Seredenina
et al., 2017) were contacted for additional information, with additional
data received from two studies (Fillman et al., 2013; Schnieder
et al., 2014). A total of 12 studies were included in the microglia
density meta-analysis, with a total of 238 patients and 252 controls
(Table S6). These studies encompassed 12 different brain regions.
Most studies analyzed microglial density and a few studies also inves-
tigated changes in microglial morphology. Various markers were used
to visualize microglia: HLA-DR, Iba1, CD68, and NOX2. NOX2 was
used in only one study (Seredenina et al., 2017) (Table S7). HLA-DR
and CD68 are upregulated on activated microglia, whereas Iba1 is
more stably expressed. NOX2 has not been used before for assessing
microglia density, but the authors show that the protein is expressed
on microglia, and this was confirmed by the study of Patir (Patir
et al., 2019). An overview of the included studies and extracted data
can be found in Tables S5-8.
3.2 | Quality assessment
A quality assessment was performed for all studies assessing method-
ology, study design, and reporting. The overall quality of the studies
was rated high. Most studies ruled out neuropathology, described
their applied methods extensively, performed case–control matching,
and reported important confounders (age/PMI/sex). Correction for
these confounders was also often applied. As expected, more recent
studies scored higher on these quality measures than some of the ini-
tial studies. As microglia activation can be caused by a variety of rea-
sons, a full description of demographics can be helpful. However, this
was present in only half of the studies.
3.3 | Review and meta-analysis of microglial
density
A random-effects meta-analysis was performed on 12 studies to ana-
lyze differences in microglial density irrespective of brain region. Esti-
mated ES for different brain regions within one study was nested to
prevent overrepresentation. Figure 1a showed no significant differ-
ences in microglial density between SCZ patients and controls (ES:
0.154 95% CI −0.113-0.421, p = .258). Unnested data displayed simi-
lar results (ES: 0.183 95% CI: −0.000 to 0.365 p = .05; Figure S2). The
heterogeneity for the studies was low to moderate (I2 = 18.9%), and
the variability between studies was not significant (Q = 18.4, p = .06).
Inspection of the funnel plot and the Egger's test showed indication
for publication bias (p = .01) (Figure S4). Two studies were defined as
potential outlier studies, exceeding residual z-scores of 1.96
(Radewicz, Garey, Gentleman, & Reynolds, 2000; Wierzba-Bobrowicz,
Lewandowska, Lechowicz, Stepien, & Pasennik, 2005)). Sensitivity
analysis, excluding these outlier studies, indicated no significant differ-
ences between SCZ and controls in microglia cell density (ES: 0.010
95% CI: −0.197 to 0.217). A meta-regression analysis checked for
potential confounder variables (age, gender, pH, and PMI) showed
SNIJDERS ET AL. 5
that none of these variables had a significant effect on the outcome
(p > .05; data not shown). An exploratory subgroup analysis was per-
formed to assess possible sources of variation. No significant differ-
ences were observed in microglia density between different microglia
markers (HLA-DR, CD68, Iba1, NOX2), automated or manual counting
methods, or cortical or subcortical studies (data not shown). When
segregating the analysis per brain regions, we found a significant
increase in microglial density in the temporal cortex (ES: 2.27 95% CI:
1.469–3.090, p < .001, Q-between = 29.72; p < .001) in SCZ patients,
but this was not observed in the other brain regions (frontal and
occipital cortex or limbic system; Figure S3). However, the two tem-
poral cortex studies were identified as potential outliers, exceeding
residual z-scores of 1.96 (Radewicz et al., 2000; Wierzba-Bobrowicz
et al., 2005).
3.4 | Review of microglial morphology
Table S8 provides an overview of studies that assessed the morphol-
ogy of microglia in SCZ. Three studies did not observe morphological
changes (Brisch et al., 2017; Petrasch-Parwez et al., 2020; Schnieder
et al., 2014). Three studies reported morphological differences
between patients and controls, but the direction of results was differ-
ent: Wierzba et al. reported an increased density of both ramified and
amoeboid cells (Wierzba-Bobrowicz et al., 2005); Hercher et al.
reported the presence of cells with an amoeboid morphology in white
matter in 3/20 SCZ patients but none of the controls (Hercher,
Chopra, & Beasley, 2014); while Radewicz et al. reported that
microglia tended to have more ramified processes in SCZ (Radewicz
et al., 2000).
F IGURE 1 Meta-analysis
microglial cell density and newly
generated microglial cell density
data in the temporal cortex of
patients with schizophrenia and
controls from the Netherlands
Brain Bank (NBB) and Edinburgh
Brain Bank (EBB). (a) Forest plot
of primary meta-analysis of
studies assessing microglial cell
density in schizophrenia (SCZ)
postmortem brain tissue. Data
from different regions in one
study were nested to prevent
overrepresentation. The forest
plots in both graphs show the
data included in a random effects
meta-analysis, representing effect
sizes (Hedges's g0) with
95 confidence interval (CI) for
differences between patients
with SCZ and controls in each
study. The Square size is
proportional to study weight.
Diamonds at the bottom of the
graphs reflect the pooled effect
sizes. (b) Representative pictures
of the microglial staining of the
temporal cortex of patients with
schizophrenia (SCZ) and controls
using immunohistochemistry with
antibodies to ionized calcium-
binding adaptor molecule (Iba1).
(c) The density of microglia
(microglia/mm2) and percentage
of the area covered with Iba1+
staining were quantified
automatically using imageJ. Grey
dots represent the controls
(N = 16), blue dots the patients
(N = 12), horizontal lines the
median expression [Color figure
can be viewed at
wileyonlinelibrary.com]
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3.5 | Microglial density and morphology NBB
and EBB
To further explore previous findings in the temporal cortex, microglial
density and morphology were assessed in a new postmortem brain
tissue SCZ cohort using immunostainings for microglial marker Iba1
(Figure 1b,c). Morphological assessment did not show microglia differ-
ences between patients and controls (Table S9). We quantified micro-
glial density using two parameters: Iba1-covered area and Iba1+ cells/
mm2. The correlation between these parameters was 0.57 (p = .008).
The number of Iba1+ cells/mm2 and total Iba1-covered area were not
different from controls (Iba1+-cells/mm2: SCZ: 111.3 ± 34.1; control
107.4 ± 55.0, p = .82; Iba1-covered area: SCZ: 5.28 ± 2.35; control
5.23 ± 1.69, p = .47). Age, PMI and pH were associated with microglial
density and Iba1-covered area. Controlling for these covariates using
an ANCOVA did not change this result (Iba1+-cells/mm2: F1,14 = 0.10,
p-value = .74, partial ŋ2 = 0.008; total Iba1-covered area: F1,14 = 0.35,
p-value = .57, partial ŋ2 = 0.03). The current study was included in the
meta-analysis described before (Figures S10–S12). Overall, the results
did not change and microglial density did not differ between SCZ
patients and controls (ES: 0.144 95% CI: 0.102–0.390, p = .250;
Figure S10). When analyzing the different brain regions including the
current study, we still found a significant increase in microglial density
in the temporal cortex compared to the other brain regions, albeit the
effect size was smaller (ES: 1.256 95% CI: 0.55–1.96, p < .001,
Qbetween = 16.4, p < .001; Figure S12).
3.6 | Microglial gene expression studies
Following our systematic search for gene expression of microglial
markers, 85 records were found in PubMed and EMBASE, from which
seven studies were finally included (Figure S5; Table S10). An over-
view of quality assessment, included studies in meta-analysis, and
extracted data can be found in Tables S11–S13. A total of 255 patients
and 261 controls were analyzed (Table S12). These studies
encompassed four different brain regions (frontal including DLPFC),
temporal, cingulate cortex, and hippocampus) (Table S13).
3.7 | Review and meta-analysis of expression
microglial markers
A random-effect meta-analysis revealed a significant decrease in gene
expression of microglial markers for unnested outcomes (ES: −0.420
95% CI −0.216 to −0.624, p < .0001, Figure 2). Exploratory subgroup
analyses revealed a significant decreased expression of microglial genes
in cortical tissues (ES: −0.553 95% CI −0.817 to −0.290, p < .0001), but
F IGURE 2 Meta-analysis on expression of microglial genes. Forest plot of primary meta-analysis on expression of microglial genes. Studies
are ordered by the microglial gene that was studied. The column “Brain region” refers to the brain region studied (DLPFC-Dorsolateral Prefrontal
Cortex; ACC-Anterior Cingulate Cortex; mACC-mid-Anterior Cingulate Cortex). Data from different regions in one study were nested to prevent
overrepresentation. The forest plots in both graphs show the data included in a random effects meta-analysis, representing effect sizes (Hedges's
g0) with 95 confidence interval (CI) for differences between patients with SCZ and controls in each study. The Square size is proportional to study
weight. Diamonds at the bottom of the graphs reflect the pooled effect sizes [Color figure can be viewed at wileyonlinelibrary.com]
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no change in subcortical tissues (ES: −0.212 95% CI −0.454 to 0.029,
p = .08; Qbetween = 3.49; p = .06; Figure S6). Further zooming in on brain
regions, a significant decrease in temporal (ES: −0.744 95% CI: −1.361
to −0.128, p = .018) and frontal cortex (ES: −0.541 95% CI: 0.810 to
−0.218, p = .001) was observed, but no change in regions related to the
limbic system (ES: −0.213 95% CI: −0.461 to 0.035, p = .092;
Qbetween = 3.87, p = .14; Figure S7). We found a significant decrease for
the marker AIF1 (ES: −0.694 95% CI: −1.168 to −0.220, p < .004), but
not for HLA-DR (Qbetween = 4.53; p = .60, Figure S8). The heterogeneity
was low to moderate (I2 = 26.7%). The Q-value indicated no significant
variability between studies (Q = 19.1, p = .162). The funnel plot and
Egger's test indicated the presence of publication bias (p = .001;
Figure S9). One study was defined as a potential outlier (Durrenberger
et al., 2015). Sensitivity analysis, excluding this potential outlier study,
did not change the results (ES: −0.319 95% CI −0.490 to −0.148,
p < .0001). None of the potential moderators (gender, age, PH, PMI and
brain bank) were associated with the ES or significantly changed hetero-
geneity (data not shown).
3.8 | Microglial gene expression NBB and EBB
mRNA expression was determined for a panel of 16 microglia-
specific markers in the temporal cortex of SCZ patients and controls
(Table 1). CSF1R, IFR8, ITGAX, OLR1, and TMEM119 were signifi-
cantly downregulated. CX3CR1, HLA-DRA, ITGAM, ITGB2, and
P2RY12 were also downregulated in SCZ patients (Figure 3a), but
these genes did not survive correction for multiple testing. Age, sex,
and PMI were associated with microglial gene expression. However,
controlling for age, sex, and PMI using an ANCOVA did not change
the results, except ITGAM lost significance after correction
(F1,18 = 2.12, p-value = .162, partial ŋ
2 = 0.106). No significant dif-
ferences were observed for AIF1, CD68, GPR34, ITGB2, TGFB2,
TREM2, TYROBP between SCZ patients and controls. We included
our novel data of the NBB/EBB cohort in our meta-analysis of pub-
lished studies (Figure S13–S16). These analyses also showed a sig-
nificant decrease in gene expression of core microglial genes (ES:
−0.417 95% CI: −0.417 to −0.546, p < .0001; Figure S13). To fur-
ther validate these findings, we compared our qPCR results with
results of the most recent transcriptome meta-analysis (Gandal,
Zhang, et al., 2018) (Table 1). CSF1R, OLR1, IRF8, CX3CR1, HLA-DR,
ITGAM, ITGAX, P2RY12, and TMEM119 were significantly down-
regulated in both studies. Altogether, we found an unaltered density
of Iba1+ cells, but decreased gene expression of several microglial
markers. These results could be an indication of an altered overall
microglial phenotype with decreased expression of several markers.
However, recent studies have shown that microglia are a heteroge-
neous cell population that consists of clusters with different
TABLE 1 qRT-PCR measured expression of 16 microglia-specific genes in postmortem temporal cortex brain tissue lysates of schizophrenia
patients compared to healthy controls. Samples derived from the Netherlands Brain Bank and Edinburgh Brain Bank are compared to gene
expression results extracted from the genome-wide RNA-sequencing study performed by the PsychENCODE consortium described by Gandal,











AIF1 0.032 (0.027) 0.044 (0.040) 0.454 −0.192**
CD68 0.009 (0.011) 0.005 (0.005) −0.989 −0.065
CSF1R 0.009 (0.008) 0.001 (0.001) −3.306** −0.176**
CX3CR1 0.052 (0.029) 0.026 (0.047) −0.956* −0.464**
GPR34 0.001 (0.006) 0.014 (0.030) 0.553 −0.216**
HLA-DRA 0.067 (0.063) 0.028 (0.035) −1.279* −0.129*
IRF8 0.004 (0.003) 0.002 (0.002) −2.945** −0.229**
ITGAM 0.001 (0.001) 0.0004 (0.0005) −1.618* −0.166**
ITGAX 0.006 (0.006) 0.001 (0.002) −2.535** −0.305**
ITGB2 0.011 (0.009) 0.003 (0.005) −1.894* −0.095
OLR1 0.004 (0.003) 8.908E-05 (9.606E-05) −5.500** −0.215**
P2RY12 0.012 (0.008) 0.003 (0.003) −1.716* −0.416**
TGFB1 0.007 (0.005) 0.009 (0.009) 0.379 0.066*
TMEM119 0.004 (0.004) 4.843E-05 (4.165E-05) −6.532** −0.237**
TREM2 0.003 (0.003) 0.003 (0.004) −0.169 −0.245**
TYROBP 0.016 (0.014) 0.034 (0.035) 1.108 −0.132*
Note: Genes marked in bold are significantly downregulated in SCZ patients in our dataset and Gandal et al. after correction for multiple testing (Gandal,
Zhang, et al., 2018).
Abbreviations: EBB, Edinburgh Brain Bank; Log2FC, Log2 fold change; NBB, Netherlands Brain Bank; SCZ, schizophrenia.
*p-value < .05; **Adjusted p-value < .05.
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characteristics (Grabert et al., 2016; Masuda, Sankowski,
Staszewski, & Prinz, 2020; Mathys et al., 2017; Prinz, Priller,
Sisodia, & Ransohoff, 2011; Van Wageningen et al., 2019). The sep-
aration between some of these clusters and macrophages is chal-
lenging. Our results could, therefore, also reflect shifts in
subclusters of microglia/myeloid cells. To further explore these two
possibilities at the protein level, we performed double-labeled
immunostainings with Iba1 and TMEM119 antibodies (Figure 3b).
Co-localization analysis showed that SCZ patients had significantly
less microglia that were positive for both Iba1 and TMEM119 in the
temporal cortex (p = .027) (Figure 3c), which indicates a shift in sub-
sets of microglia/myeloid cells. We observed donor-donor differ-
ences in the morphology of TMEM119+ cells, but did not find an
association with disease status.
3.9 | Comparing the expression levels of microglia-
specific genes in bulk tissue across disorders
To further understand how the phenotype of microglia is changed in
SCZ, a set of microglia-specific genes (N = 243) (Patir et al., 2019) and
available results from the aforementioned transcriptome study
(Gandal, Zhang, et al., 2018) were analyzed. In SCZ, 90/243 microglia-
specific genes are downregulated, and 7 are upregulated (Table S14).
Downregulated genes include C3, P2RY12, P2RY13, CSF1R, CX3CR1,
TMEM119, ITGAM, ITGAX, OLFML3. A cross-disorder analysis demon-
strated that expression changes of these microglia-specific genes are
correlated between SCZ and ASD or BD (Figure 4a). Interestingly,
most of these 243 microglia-specific genes were upregulated in AD,
but downregulated in SCZ (Figure 4b). Thirty-seven genes showed an
F IGURE 3 Expression of a panel of microglial genes in the temporal cortex of patients with schizophrenia and controls from the Netherlands
Brain Bank and Edinburgh Brain Bank. (a) mRNA expression levels of a panel of microglial genes in controls (N = 14, grey dots) and patients with
schizophrenia (SCZ; N = 9, blue dots) as determined in the temporal cortex by qPCR. Horizontal lines show median expression. Non-parametric
testing was applied. *p < .05, **p < .010, ***p < .001. (b) Paraffin sections of temporal cortex of controls (N = 19) and patients with SCZ (N = 18)
were stained with antibodies to Iba1 (green) and TMEM119 (red), and nuclei visualized using Hoechst (blue). Representative pictures for the two
groups are shown: White arrow in control represents positive staining for TMEM119/Iba1, white arrow in in schizophrenia represents positive
staining for Iba1, but negative staining for TMEM119. (c) The quantification of the percentage of TMEM119+/Iba1+ of the total population of
Iba1+. Number 1 and 2 refer to the donors that are also shown in the stainings of Figure 3b. Horizontal lines show median expression. Non-
parametric testing was applied. *p < .05 [Color figure can be viewed at wileyonlinelibrary.com]
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opposite effect in these disorders, being upregulated in AD and down-
regulated in SCZ. These included CD33, TREM2, TMEM119, CSF1R,
and TLR10.
4 | DISCUSSION
The aim of the present study was to provide an update of the micro-
glial changes that have been found in postmortem brain tissue of
patients with SCZ. We systematically investigated published studies
assessing microglial cell density, morphology and expression of micro-
glial genes in postmortem brain tissue of SCZ patients and performed
additional experiments on temporal cortex of a separate and new
cohort.
4.1 | Microglial density and morphology in SCZ
Previous reviews by Trepanier and Van Kesteren reported evidence for
an increased microglial density in SCZ (Trépanier et al., 2016; Van
Kesteren et al., 2017). Here, we included 10 additional studies (Brisch
et al., 2017; Durrenberger et al., 2015; Fiorentino et al., 2016; López-
González et al., 2019; Nakatani et al., 2006; Petrasch-Parwez
et al., 2020; Schmitt et al., 2011; Schnieder et al., 2014; Seredenina
et al., 2017; Sinkus, Adams, Logel, Freedman, & Leonard, 2013) and
excluded two studies with overlapping samples (Gos et al., 2014;
Steiner et al., 2008), as well as one study that had a strong effect in the
previous reviews (ES: 1.79 95% CI 0.76–2.83), but was retracted
because of data falsification (Rao, Kim, Harry, Rapoport, &
Reese, 2013). In addition, we applied a nesting approach on studies
F IGURE 4 Cross-disorder
analysis. (a) Comparison between
transcriptional changes of a set of
microglial signature genes
(N = 243) in bulk brain tissue
across diseases. Log2 fold
changes of 243 core microglial
genes assessed in cortex of
patients with schizophrenia (SCZ)
(Gandal, Zhang, et al., 2018),
plotted against the log2 fold
changes reported in cortex of
patients with Alzheimer's Disease
(AD) (Friedman et al., 2018),
Autism Spectrum Disorder (ASD)
and Bipolar Disorder
(BD) (Gandal, Zhang, et al., 2018).
Spearman correlation and p-
values are provided. (b) Overlaps
between the number of microglia
signature genes up- or
downregulated in SCZ, ASD, AD,
and BD. Well-known microglial
markers are highlighted; genes in
bold are significantly upregulated
in AD, but downregulated in SCZ
[Color figure can be viewed at
wileyonlinelibrary.com]
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including multiple brain regions. The heterogeneity of our updated
meta-analysis was lower compared to the previous study (Van Kesteren
et al., 2017), and we no longer found a significant difference in micro-
glial density in SCZ. A significantly increased microglial density was only
found in the temporal cortex. However, that result was based on two
smaller studies (N = 18 and N = 17 in total) (Radewicz et al., 2000;
Wierzba-Bobrowicz et al., 2005) that were identified as potential out-
liers with methodological limitations, as reported in the qualitative
assessment. In addition, we were not able to validate an increased den-
sity in the temporal cortex of an additional cohort, with the limitation
that the sample size of our additional cohort was also limited (N = 28 in
total). Although we found several studies reporting on morphological
changes, the results were inconsistent, which is probably related to the
large variety of read-outs that were used on studies with small sample
sizes and the challenges in quantifying morphological assessments.
4.2 | Microglial gene expression in SCZ
The previous reviews reported indications for neuroinflammation. In
both studies, the authors included mRNA and protein expression of a
variety of inflammatory markers (Trépanier et al., 2016; Van Kesteren
et al., 2017), such as IL-6, IL-1β, and IL-8, which are not specific to
microglia, but are also expressed in astrocytes and other cell types in
the brain. In addition, the results were heterogeneous and except for an
increased expression of IL6, increased expression of these markers was
not found in the most recent and robust transcriptome meta-analysis
(Gandal, Zhang, et al., 2018). Since we were specifically interested in
microglia, we only included expression of a set of microglial-specific
genes (Patir et al., 2019). Our qPCR analysis, our meta-analysis, and the
most recent genome-wide transcriptomic analysis all show a consistent
decreased expression of several microglial genes, including the well-
known markers HLA-DRA and ITGAM. It would be interesting to under-
stand how the observed findings relate to the binding of the TSPO
tracer. Positron emission tomography studies with TSPO tracers have
been often used to analyze neuroinflammation or microglial activation
in vivo. TSPO PET studies in schizophrenia patients have shown hetero-
geneous results. While the earlier studies reported increased binding of
the tracers, more recent studies did not find this effect or even a lower
binding (Marques et al., 2019; Plavén-Sigray et al., 2018). Moreover,
there is a debate about what type of changes in glial cells are reflected
by changes in TSPO binding (Notter, Coughlin, Sawa, & Meyer, 2018;
Owen et al., 2017; Sneeboer et al., 2020). Our current study illustrates
that microglial changes go beyond the activated/non-activated dichot-
omy. The microglia signature that we describe here may provide novel
molecular imaging targets.
4.3 | Translation of gene expression changes to
cellular changes
In our meta-analysis and additional immunostainings, we did not find
indications for changes in microglial density. In our gene expression
analyses, we found decreased expression of several microglia-specific
genes, including P2RY12, CSF1R, and TMEM119. To further explore
these findings at the cellular level, we performed a staining with Iba1
and TMEM119 and found a decreased percentage of Iba1 cells
expressing TMEM119. TMEM119 has recently been identified as a
marker that is highly specific to microglia (Bennett et al., 2016; Satoh
et al., 2016). In contrast to Iba1, which is also expressed on infiltrating
macrophages (Imai, Ibata, Ito, Ohsawa, & Kohsaka, 1996; Ohsawa,
Imai, Kanazawa, Sasaki, & Kohsaka, 2000), it is exclusively expressed
on microglia. Although the function of TMEM119 is still unknown, it
has been identified as a downstream target of PU.1, a protein that is
involved in microglia development (Satoh et al., 2016). TMEM119 is
highly expressed on subclusters of microglial cells with more homeo-
static properties, and this subcluster is partly lost with increasing age
and in neurodegeneration as observed in Alzheimer's disease and
amyotrophic lateral sclerosis brain tissue (Chiu et al., 2013; Holtman
et al., 2015; Krasemann et al., 2017; Olah et al., 2018; Orre
et al., 2014). These results suggest that microglia in schizophrenia do
not all show the same changes in phenotype, but that there is a
change in the composition of the microglia population in schizophre-
nia, similar to what has been shown for neurodegenerative disorders
(Srinivasan et al., 2020). In addition, it is important to note that Iba1 is
a marker that is often used as a marker for microglia, but that this
marker is not restricted to microglia and also expressed at lower levels
on for instance, infiltrating macrophages (Imai et al., 1996; Ohsawa
et al., 2000). We performed a systematic search for the macrophage
markers ITGA4, CD44, CD169, CD38, CD11a, PDL1 (see Figure S17)
(Bowman et al., 2016; Greter, Lelios, & Croxford, 2015; Gu
et al., 2016; Mrdjen et al., 2018), but we did not find any relevant arti-
cles. In addition, we extracted the data of these markers from the larg-
est transcriptome meta-analysis to date (Gandal, Haney, et al., 2018;
Gandal, Zhang, et al., 2018). Except for a decreased expression of
CD44, we found no indications for SCZ-associated changes in infil-
trating macrophages (Table S15). Analyses at the single-cell level, such
as mass cytometry (Böttcher et al., 2019; Sneeboer et al., 2019;
Snijders et al., 2020) or single nuclei RNA-seq (Masuda et al., 2020;
Mathys et al., 2019) are needed to further understand how the com-
position of myeloid cells is changed in schizophrenia.
4.4 | Interpretation of the identified SCZ-
associated microglial gene expression changes
Here we describe a panel of various microglial-specific genes that are
consistently downregulated in SCZ. These changes showed similarities
with other psychiatric disorders, but a distinct profile from AD. An
important limitation for this cross-disorder analysis, however, is that
the AD data were derived from a separate transcriptome analysis
(Friedman et al., 2018) rather than the combined analysis of different
psychiatric disorders (Gandal, Zhang, et al., 2018). Many factors can
potentially be involved in causing this SCZ-related microglial profile,
characterized by a loss of mature characteristics but without signs of
overt immune activation. We have summarized some of the potential
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candidates in Figure 5. This includes a response of microglia to stress,
a well-known risk factor for developing psychiatric disorders (Zorn
et al., 2017). Animal studies revealed that stress can induce a down-
regulation of similar microglial markers as observed in SCZ postmor-
tem brain tissue, such as CX3CR1, P2RY12, and TGFBR1 (Park
et al., 2019). This microglial phenotype may also be a consequence of
disrupted TGF-β signaling, which is important for inducing and
maintaining the distinct profile of microglia (Butovsky et al., 2014;
Gosselin et al., 2017). The changes we observed showed a high
resemblance with changes induced by culturing microglia after isolat-
ing them from postmortem brain tissue. However, these changes are
counteracted when the cells are supplemented with TGF-β (Gosselin
et al., 2017). An overrepresentation of the TGF-β signaling pathway in
SCZ risk genes further supports this hypothesis (Chavarría-Siles
et al., 2007; Frydecka et al., 2013). Upstream from those gene expres-
sion changes might be epigenetic changes previously described for
SCZ. The largest methylation study to date (Jaffe et al., 2015) found
differential methylation of several transcription factors that are
related to microglia development and phenotype, including MAFB,
FOS, RUNX1, and MEF2C (Gosselin et al., 2017; Jaffe et al., 2015;
van Mierlo et al., 2019). In addition to these potential causal path-
ways, this microglial signature may have also been triggered by any of
the consequences of having SCZ, such as the use of medication (A.
Bloomfield et al., 2018; Cotel et al., 2015; Kato et al., 2011) or an
altered lifestyle since unhealthy diet, less physical activity and sleep,
and obesity can all cause changes in microglia (Ingiosi, Opp, &
Krueger, 2013; Jamatia et al., 2018; Valero, Paris, & Sierra, 2016).
Whether the changes that we observed are involved in causing
the disease is not known yet. In Figure 6 we speculate how the
observed microglial changes could potentially contribute to the
pathogenesis of SCZ. This includes dysregulation of the normal
functions of microglia in neuroplasticity and neurotransmission by
affecting the crosstalk between microglia, neurons, and astrocytes
(Cserép et al., 2020). For instance, mice with CX3CR1 deletion
exhibit reduced dendritic spine pruning, abnormal synapse matura-
tion, decreased functional connectivity, and behavioral abnormali-
ties (Paolicelli et al., 2011). Recently, increased phagocytosis and
increased inflammation were observed in a cellular model that
deleted the CX3CR1 gene in microglia derived from human induced
pluripotent stem cells (hiPSC), suggesting that CX3CR1 in human
microglia may contribute to microglial homeostasis by regulating
inflammatory response and phagocytosis (Murai et al., 2020).
Abnormalities in synaptic maturation, synapse elimination and spine
density are thought to underlie SCZ, but also contribute to other
psychiatric disorders, including ASD and BD (Gandal, Zhang,
et al., 2018; Penzes, Cahill, Jones, Vanleeuwen, & Woolfrey, 2011).
In addition, these microglial changes could also be involved in
dopamine dysregulation in SCZ (Jaaro-Peled, Ayhan, Pletnikov, &
Sawa, 2010). P2RY12 and related genes have been shown to play
an important role in dopamine signaling (Krügel, Kittner, Franke, &
Illes, 2001; Trendelenburg & Bültmann, 2000; Zhang, Yamashita,
Ohshita, Sawamoto, & Nakamura, 1995). Our findings stress the
need for more research to understand how changes in the molecu-
lar phenotype of microglia are related to changes in microglia–
F IGURE 5 Schematic
representation of potential
causes of the observed microglia
signature in SCZ. This figure
summarizes the results from our
study and suggests how these
findings may interact and cause
(or contribute) to SCZ [Color
figure can be viewed at
wileyonlinelibrary.com]
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neuron interactions and how this influences brain development and
function.
4.5 | Strengths and limitations
Evidence for inflammation in postmortem brain tissue of SCZ patients
has been reviewed before (Trépanier et al., 2016; Van Kesteren
et al., 2017), but these studies combined different types of outcomes
into one analysis. This can be problematic, since gene expression, pro-
tein expression and cell density do not necessarily correlate (Liu,
Beyer, & Aebersold, 2016). In this study, we used a more conservative
approach by separating density measures from gene expression out-
comes. In addition, we prevented the overrepresentation of particular
populations by excluding studies with overlapping samples. Subgroup
analysis outcomes were performed on a limited number of studies
and may have been susceptible to the influence of an outlier. Our
comparative analysis may provide direction in the search for underly-
ing mechanisms through the identification of circumstances similar
and different to SCZ. However, the data on SCZ we used for compari-
son originated from bulk brain tissue sequencing, and it recently
became clear that microglia-specific changes are underrepresented in
bulk data (Mathys et al., 2019). Although we selected genes that are
strongly enriched in microglia, expression by other cell types could
have contributed to the outcome. Thus, the exact microglia-specific
changes in SCZ remain to be determined. In addition, many factors,
such as neuroleptics (Kowalski, Labuzek, & Herman, 2003) and use of
second-generation antipsychotics (Kato et al., 2011; Bloomfield
et al., 2018; Cotel et al., 2015), cause of death, suicide attempts, somatic
comorbidity (Mathys et al., 2019; Mizee et al., 2017; van der Poel
et al., 2019), chronicity (Bitanihirwe & Woo, 2020), positive or negative
symptomatology (Volk, 2017), age and sex may confound the results.
We were not able to fully adjust for all these potential confounding
effects in additional analyses due to small sample sizes in our own
cohort and limited reporting across studies in the meta-analysis.
4.6 | Conclusions
Altogether we have found evidence for the presence of a distinct
microglia phenotype in SCZ with potential overlap with other psychiat-
ric disorders. The microglial gene expression changes identified in bulk
brain tissue of SCZ patients need to be confirmed through sequencing
of pure microglia populations by either isolating them from non-frozen
brain tissue (Melief et al., 2016) or using nuclei-based techniques (Nott
et al., 2019). Single-cell/nuclei techniques (Masuda et al., 2020) will also
uncover whether these changes are reflecting changes in the entire
microglial population or just a subpopulation. The impact of these SCZ-
associated transcriptomic alterations on microglial function and, ulti-
mately, the influence on brain development and function is important
for understanding the relevance of these findings and will rely on stud-
ies in cell-culture and animal models.
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